<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15101">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02099708</url>
  </required_header>
  <id_info>
    <org_study_id>467-713</org_study_id>
    <nct_id>NCT02099708</nct_id>
  </id_info>
  <brief_title>Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs</brief_title>
  <official_title>Takepron Capsules 15/ Orally Dispersing（OD） Tablets 15 Special Drug Use Surveillance Long-term Use Survey on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of long-term
      administration of lansoprazole (Takepron) therapy for up to 12 months in the routine
      clinical setting in patients receiving oral non-steroidal anti-inflammatory drugs (NSAIDs)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a special survey on long-term use (for up to 12 months) of lansoprazole (Takepron)
      to determine the incidence of adverse drug reactions in the routine clinical setting in
      patients receiving non-steroidal anti-inflammatory drugs (NSAIDs).

      The usual adult dosage is 15 mg of lansoprazole administered orally once daily.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Frequency of adverse drug reactions</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Frequency, severity, and time to onset of adverse drug reactions tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions..</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset of gastric or duodenal ulcers or hemorrhagic lesions after the start of administration of lansoprazole</measure>
    <time_frame>From baseline to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Summary of data on the presence or absence of endoscopic examinations, onset of gastric or duodenal ulcers, onset of gastric or duodenal hemorrhagic lesions, and details of treatment and outcome of treatment for gastric or duodenal ulcers or hemorrhagic lesions.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3502</enrollment>
  <condition>Gastric or Duodenal Ulcers</condition>
  <arm_group>
    <arm_group_label>Lansoprazole 15 mg</arm_group_label>
    <description>Lansoprazole 15 mg orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Lansoprazole Capsules 15/ OD Tablets 15</description>
    <arm_group_label>Lansoprazole 15 mg</arm_group_label>
    <other_name>Takepron Capsules 15, Takepron OD Tablets 15</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Gastric or duodenal ulcers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) Patients with a history of gastric or duodenal ulcers (2) Patients requiring
             long-term use of NSAIDs for reasons such as pain management for rheumatoid arthritis
             or osteoarthritis (3) Patients taking oral NSAIDs at the start of administration of
             lansoprazole (including patients who start NSAIDs on the same day as the start of
             administration of lansoprazole)

        Exclusion Criteria:

          -  (1) Patients with gastric or duodenal ulcer (in the active [A1, A2] or healing [H1,
             H2] stage if assessed endoscopically) at the start of administration of lansoprazole
             (2) Patients with active upper gastrointestinal hemorrhage at the start of
             administration of lansoprazole (3) Patients with contraindications for lansoprazole
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Postmarketing Group Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>March 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacological therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Duodenal Ulcer</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
